Arrowhead receives regulatory clearance to begin Phase 1/2 study of ARO=HBV for treatment of Hepatitis B (5.47)
- The company anticipates that dosing will begin around the end of March.
- The study, AROHBV1001 (NCT03365947), is a Phase 1/2 study to evaluate the safety, tolerability, and pharmacokinetic effects of single-ascending doses (SAD) of ARO-HBV in healthy adult volunteers, and to evaluate the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses (MAD) of ARO-HBV in patients with chronic HBV.